Debt-to-equity of Citius Pharmaceuticals, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Citius Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Citius Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 86%, a 262% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Citius Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 86% +62% +262% 30 Sep 2025
Q2 2025 81% +68% +505% 30 Jun 2025
Q1 2025 58% +44% +333% 31 Mar 2025
Q4 2024 39% +25% +188% 31 Dec 2024
Q3 2024 24% +11% +91% 30 Sep 2024
Q2 2024 13% +1.8% +15% 30 Jun 2024
Q1 2024 13% +2.6% +24% 31 Mar 2024
Q4 2023 13% +3.9% +41% 31 Dec 2023
Q3 2023 12% +3% +31% 30 Sep 2023
Q2 2023 12% +3% +34% 30 Jun 2023
Q1 2023 11% +2.7% +33% 31 Mar 2023
Q4 2022 9.5% +1.6% +20% 31 Dec 2022
Q3 2022 9.5% 30 Sep 2022
Q2 2022 8.7% 30 Jun 2022
Q1 2022 8.1% 31 Mar 2022
Q4 2021 7.9% 31 Dec 2021
Q3 2020 26% 30 Sep 2020
Q2 2020 27% 30 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.